(Q37571446)

21 August 2017

1 reference

title

Imatinib and beyond--exploring the full potential of targeted therapy for CML. (English)

1 reference

21 August 2017

1 reference

2

Hagop Kantarjian

1 reference

21 August 2017

3

Jorge Cortes

1 reference

21 August 2017

author name string

Alfonso Quintás-Cardama

series ordinal

1

1 reference

21 August 2017

language of work or name

English

0 references

publication date

4 August 2009

1 reference

Nature Reviews Clinical Oncology

21 August 2017

published in

1 reference

21 August 2017

volume

6

1 reference

21 August 2017

issue

9

1 reference

21 August 2017

page(s)

535-543

1 reference

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

15-deoxy-delta12,14-PGJ2 enhances platelet production from megakaryocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Molecular biology of bcr-abl1-positive chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using str

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Hematopoietic stem cell transplantation from unrelated donors for acute leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

PML targeting eradicates quiescent leukaemia-initiating cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Flying under the radar: the new wave of BCR-ABL inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

EKLF restricts megakaryocytic differentiation at the benefit of erythrocytic differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Homoharringtonine: history, current research, and future direction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Analysis of the spatial and temporal characteristics of platelet-delivered factor VIII-based clots

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.112

Tyrosine kinase inhibitors for chronic myelogenous leukemia.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19652654

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19652654

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2009.112

1 reference

21 August 2017

1 reference